The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...

The Greek Orthodox Archdiocese of America Center for Family Care announces the awarding of a generous grant from Lilly Endowment Inc. for the establishment of a new initiative On Behalf of All: Toward ...

All the evidence gathered from the five-year trial will be used to demonstrate the long-term effect of weight loss medication ...

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...